289 results match your criteria: "Transient Acantholytic Dermatosis"
Grover's disease-like patterns in early pityriasis rubra pilaris.
J Dtsch Dermatol Ges
November 2024
Department of Dermatology, University of Heidelberg, Heidelberg, Germany.
Grover's disease in oncologic patients: clinicopathologic features and systematic review.
Int J Dermatol
October 2024
Unit of Dermatology, IRCCS Ospedale San Raffaele, Milano, Italy.
ERK hyperactivation in epidermal keratinocytes impairs intercellular adhesion and drives Grover disease pathology.
JCI Insight
November 2024
Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
Article Synopsis
- Grover disease is a skin condition characterized by blistering caused by the breakdown of connections between skin cells, with its causes still unknown and no FDA-approved treatment available.
- Research has shown that B-RAF inhibitors used in cancer treatment can paradoxically lead to Grover disease by causing hyperactivation of ERK, which disrupts skin cell cohesion.
- The study suggests that inhibiting MEK can prevent the onset of Grover disease by controlling ERK activation, indicating a potential therapeutic approach that could benefit both Grover disease and similar genetic conditions like Darier disease.
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis.
J Psoriasis Psoriatic Arthritis
October 2023
Article Synopsis
- The article DOI: 10.1177/2475530320970530 has been amended to address inaccuracies or errors found in the original work.
- The corrections made aim to improve the clarity and credibility of the information presented.
- Readers are encouraged to refer to the updated article for the most accurate and reliable content.
Grover's Disease Association with Cutaneous Keratinocyte Cancers: More than a Coincidence?
Int J Mol Sci
September 2024
Pathophysiology Department, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Article Synopsis
- * There is a noted but poorly defined connection between GD and cutaneous keratinocyte carcinomas, specifically non-melanoma skin cancers (NMSCs), with very few studies highlighting this relationship between 1983 and 2024.
- * GD has been misdiagnosed as various NMSCs, and understanding this connection could provide insights into its underlying mechanisms, possibly reclassifying GD as a unique syndrome.
Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy.
An Bras Dermatol
August 2024
Department of Dermatology, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Madrid, Spain.
Article Synopsis
- Transient acantholytic dermatosis, or Grover's disease, is a skin condition that causes red, itchy bumps mainly on the trunk, mostly seen in men over 50, and can be triggered by heat, sweat, sun exposure, and some medications.
- A case study highlighted a 65-year-old man with a severe rash and a confirmed SARS-CoV-2 infection, who developed COVID-19 pneumonia, showing the link between Grover's disease and COVID-19.
- The patient’s skin lesions improved with corticosteroids, suggesting that awareness of Grover's disease in COVID-19 patients is important for diagnosis and treatment.
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Am J Clin Dermatol
July 2024
Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Article Synopsis
- Cutaneous immune-related adverse events include various skin reactions like lichenoid reactions and severe conditions like Stevens-Johnson syndrome, often treated with high-dose systemic corticosteroids.
- The use of corticosteroids can hinder antitumor responses and lead to complications, prompting the exploration of corticosteroid-sparing targeted immunomodulators as alternatives.
- Biologic agents, effective for non-cutaneous immune-related issues, are gaining recognition for their ability to treat diverse cutaneous reactions, though more research is needed on their long-term impact on cancer treatment.
Papular acantholytic dermatosis: a rare cause of genital rash.
Clin Exp Dermatol
September 2024
Departments of Dermatology and Venereology.
Successful treatment of resistant Grover's disease with dupilumab.
Int J Womens Dermatol
June 2024
River Ridge Dermatology, Blacksburg, Virginia.
Acantholytic Dyskeratosis Consistent With Grover's Disease After Letrozole Therapy.
Cureus
February 2024
Dermatology, Family Dermatology of North Florida, Tallahassee, USA.
Article Synopsis
- A case study details a 66-year-old woman with stage IV breast cancer who developed Grover's disease (GD) while being treated with letrozole, a common breast cancer medication.
- GD is characterized by itchy skin lesions typically on the chest and trunk, and in this case, it was initially misdiagnosed as contact dermatitis.
- After stopping letrozole and using topical steroids, the patient's condition improved, highlighting the need for awareness of drug-induced skin reactions in cancer treatments and the limited existing research on GD related to letrozole.
Article Synopsis
- Grover's disease, or transient acantholytic dermatosis, lacks randomized control trials for treatment, relying instead on case studies and reports for evidence.
- This case series reviews current treatment methods and presents two cases of persistent Grover's disease successfully treated with low-dose oral isotretinoin, after other treatments had failed.
- The study emphasizes the potential effectiveness of low-dose systemic retinoid therapy in managing Grover's disease when conventional treatments do not work.
Atypical form of transient acantholytic dermatosis with edematous erythema.
Dermatol Reports
December 2023
Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Japan.
Methotrexate Versus Acitretin for Grover's Disease Refractory to Topical Therapies.
J Cutan Med Surg
March 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Article Synopsis
- The article discusses a case of Grover’s disease, a skin condition, that appeared in a patient after treatment with talquetamab, a medication used in certain cancer therapies.
- Grover’s disease is characterized by transient itchy red bumps on the skin, particularly in adults and often associated with warm weather.
- The authors highlight the importance of monitoring skin reactions in patients undergoing treatment with new drugs like talquetamab, suggesting that healthcare providers should be aware of possible dermatological side effects.
An Unusual Trigger of Grover's Disease (GD).
Cureus
June 2023
Dermatology, Sisters of Charity Hospital, Buffalo, USA.
Article Synopsis
- Grover's disease (GD) is a rare skin condition characterized by an itchy, red rash, and in this unique case, it was triggered by honeybee stings in an 80-year-old man with a history of honeybee venom allergy.
- Despite initial treatments including antihistamines and topical steroids, the patient's rash worsened and spread across multiple parts of his body, leading to significant discomfort.
- A skin biopsy confirmed the diagnosis of GD, and after five months of ineffective treatments, the patient finally responded positively to a combination of systemic steroids, high-potency topical steroids, emollients, and antihistamines.
Transcriptional profiling of rare acantholytic disorders suggests common mechanisms of pathogenesis.
JCI Insight
August 2023
Department of Pathology, and.
Article Synopsis
- Darier, Hailey-Hailey, and Grover diseases are rare skin conditions characterized by defects in cell-cell adhesion and desmosome organization, sharing common underlying mechanisms despite different causes.
- RNA-seq analysis of skin samples revealed significant overlap in transcriptomic profiles among these diseases, distinguishing them from other inflammatory skin conditions like atopic dermatitis and psoriasis.
- The study identified a unique downregulation of actin organization pathways in these diseases, linked to decreased SRF/MRTF activity, suggesting a potential target for further research and treatment approaches.
Association of Somatic ATP2A2 Damaging Variants With Grover Disease.
JAMA Dermatol
July 2023
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Article Synopsis
Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease.
JAAD Case Rep
March 2023
Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
J Cutan Pathol
June 2023
Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Article Synopsis
- A 73-year-old male with metastatic renal cell carcinoma developed both bullous pemphigoid (BP) and Grover disease (GD) while being treated with nivolumab, a type of immune checkpoint inhibitor (ICI).
- His skin condition included scaly papules and widespread lesions, with biopsies confirming both GD and BP through specific histopathological and immunofluorescence findings.
- The relationship between these ICI-induced conditions is complex, with T-cell activation potentially linking them, and the patient was effectively treated with dupilumab.
Assessment of Blue Light Phototherapy for Grover Disease: A Nonrandomized Controlled Trial.
JAMA Dermatol
January 2023
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Pruritic papules after induction chemotherapy with daunorubicin and cytarabine.
Dermatol Online J
June 2022
Department of Dermatology, University of California Davis Health, Sacramento, California, USA Department of Pathology and Laboratory Medicine, University of California Davis Health, Sacramento, California, USA.
Article Synopsis
- A 65-year-old woman developed an itchy, papular rash after starting chemotherapy for acute myelomonocytic leukemia.
- The rash improved with treatment using triamcinolone, allowing her to continue chemotherapy.
- This case highlights the occurrence of transient acantholytic dermatosis during cancer treatment and the need for careful diagnosis of skin issues in cancer patients.
Grover disease associated with docetaxel chemotherapy.
JAAD Case Rep
November 2022
Department of Dermatology, Keck School of Medicine at the University of Southern California, Los Angeles, California.
Usefulness of in-vivo reflectance confocal microscopy in patient with nivolumab induced Grover disease.
Ital J Dermatol Venerol
August 2022
Section of Dermatology, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy -
Bullous Grover's Disease in a Chinese Tibetan Adolescent: A Case Report.
Clin Cosmet Investig Dermatol
July 2022
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
Article Synopsis
- Grover's disease (GD), a rare skin condition mainly affecting elderly white men, presents with diverse skin lesions and severe itching, often leading to spontaneous remission.
- A case was reported of a 14-year-old Tibetan male in China with pruritic red papules and variously sized blisters, diagnosed through skin biopsies and other examinations that confirmed acantholysis.
- The condition was successfully treated with minocycline and methotrexate, and the patient remained recurrence-free for 19 months post-treatment.